Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma

2008

Long-term effects of G-CSF in non-Hodgkin's lymphoma

Sample size: 80 publication Evidence: moderate

Author Information

Author(s): Clamp A R, Ryder W D J, Bhattacharya S, Pettengell R, Radford J A

Primary Institution: Cancer Research UK, University of Manchester

Hypothesis

Does the use of granulocyte colony-stimulating factor (G-CSF) to maintain chemotherapy dose intensity affect long-term mortality patterns in non-Hodgkin's lymphoma?

Conclusion

The use of G-CSF did not significantly improve overall survival but was associated with a higher rate of non-lymphoma-related deaths.

Supporting Evidence

Patients receiving G-CSF had a 12% higher median dose intensity of chemotherapy.
10-year freedom from progression was significantly better in the G-CSF group (68% vs 47%).
More deaths from second malignancies and cardiovascular causes were observed in the G-CSF group.

Takeaway

This study looked at patients with non-Hodgkin's lymphoma who received a special treatment to help them tolerate chemotherapy better. While it helped some patients avoid cancer progression, it also led to more deaths from other causes.

Methodology

The study analyzed long-term follow-up data from a randomized controlled trial comparing chemotherapy alone to chemotherapy with G-CSF in patients with aggressive non-Hodgkin's lymphoma.